IPP Bureau
Alembic announces USFDA final approval for Dasatinib Tablets
By IPP Bureau - November 08, 2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Lupin Bioresearch Center receives zero observations from USFDA
By IPP Bureau - November 08, 2025
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
By IPP Bureau - November 07, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
By IPP Bureau - November 07, 2025
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
By IPP Bureau - November 07, 2025
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Amgen confident in US biosimilar market’s strength as sales surge 52%
By IPP Bureau - November 07, 2025
Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month
By IPP Bureau - November 07, 2025
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’
By IPP Bureau - November 07, 2025
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Philips reiterates FY25 outlook following steady Q3 performance
By IPP Bureau - November 07, 2025
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Sovato secures series B funding to advance remote robotic surgery platform
By IPP Bureau - November 07, 2025
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial
By IPP Bureau - November 07, 2025
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network
By IPP Bureau - November 07, 2025
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
By IPP Bureau - November 06, 2025
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Senores Pharma forms new subsidiary in US
By IPP Bureau - November 06, 2025
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
